Fayez Sarofim & Co
CME icon

Fayez Sarofim & Co’s CME Group CME Stock Holding History

Fayez Sarofim & Co’s Portfolio CME Stock Details CME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$361M Sell
1,222,003
-28,464
-2% -$8.45M 0.92% 33
2025
Q4 		$341M Buy
1,250,467
+1,171
+0.1% +$318K 0.82% 34
2025
Q3 		$338M Buy
1,249,296
+7,866
+0.6% +$2.14M 0.78% 37
2025
Q2 		$342M Sell
1,241,430
-29,452
-2% -$8.01M 0.82% 36
2025
Q1 		$337M Sell
1,270,882
-252,554
-17% -$62.3M 0.84% 39
2024
Q4 		$354M Buy
1,523,436
+53,389
+4% +$12.3M 0.86% 33
2024
Q3 		$324M Buy
1,470,047
+105,960
+8% +$21.9M 0.82% 37
2024
Q2 		$268M Buy
1,364,087
+225,024
+20% +$46.5M 0.72% 40
2024
Q1 		$245M Buy
1,139,063
+31,594
+3% +$6.64M 0.73% 41
2023
Q4 		$227M Buy
1,107,469
+356,423
+47% +$76.1M 0.69% 41
2023
Q3 		$150M Buy
751,046
+315,668
+73% +$62.7M 0.51% 51
2023
Q2 		$80.7M Buy
435,378
+246,820
+131% +$45.6M 0.28% 61
2023
Q1 		$36.1M Buy
188,558
+162,535
+625% +$29.4M 0.13% 74
2022
Q4 		$4.38M Buy
26,023
+6,760
+35% +$1.17M 0.02% 111
2022
Q3 		$3.41M Buy
19,263
+525
+3% +$104K 0.01% 119
2022
Q2 		$3.84M Buy
18,738
+1,203
+7% +$255K 0.01% 122
2022
Q1 		$4.17M Buy
17,535
+12,396
+241% +$2.91M 0.01% 128
2021
Q4 		$1.17M Buy
5,139
+413
+9% +$90.9K ﹤0.01% 197
2021
Q3 		$914K Buy
4,726
+68
+1% +$13.8K ﹤0.01% 199
2021
Q2 		$991K Buy
4,658
+1,063
+30% +$224K ﹤0.01% 208
2021
Q1 		$734K Buy
3,595
+25
+0.7% +$4.92K ﹤0.01% 198
2020
Q4 		$650K Buy
3,570
+100
+3% +$17K ﹤0.01% 195
2020
Q3 		$581K Buy
3,470
+250
+8% +$42.1K ﹤0.01% 189
2020
Q2 		$523K Buy
3,220
+1,245
+63% +$223K ﹤0.01% 188
2020
Q1 		$341K Buy
+1,975
New +$393K ﹤0.01% 200

Other funds holding CME

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fayez Sarofim & Co's CME Position: Q1 2026 in Review

Fayez Sarofim & Co reduced its CME Group (CME) stake by 2.3% in Q1 2026, selling an estimated $8.45M and leaving 1,222,003 shares worth $361M. The position accounts for 0.92% of the portfolio, ranked #33.

Fayez Sarofim & Co first reported a position in CME in Q1 2020 and has held it in 25 quarters since. 1,790 funds tracked by Wall St. Rank hold CME as of Q1 2026.

  • Fayez Sarofim & Co held 1,222,003 shares of CME Group worth $361M as of Q1 2026.
  • Fayez Sarofim & Co sold 28,464 CME Group shares in Q1 2026, an estimated $8.45M.
  • CME Group made up 0.92% of Fayez Sarofim & Co's portfolio in Q1 2026, its #33 holding.
  • Fayez Sarofim & Co first reported a position in CME Group in Q1 2020 and has held it in 25 quarters since.
  • 1,790 funds tracked by Wall St. Rank held CME Group as of Q1 2026.

Based on Fayez Sarofim & Co's 13F filing for Q1 2026, filed 15 May 2026.